Chronic Idiopathic Urticaria - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Chronic Idiopathic Urticaria - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Idiopathic Urticaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chronic Idiopathic Urticaria: Overview
Chronic Urticaria (CU) conventionally refers to recurrent wheals, on most days of the week, which occur for a period of ? six weeks. CU can be further divided into two different subtypes, namely, chronic idiopathic urticaria (also called chronic spontaneous urticaria) and chronic inducible urticaria (also called physical urticaria). In most patients, CU is a sporadic and self-limited disorder. Chronic spontaneous urticaria refers to chronic urticaria that has no specific cause or trigger. Weals are present on most days of the week for 6 weeks or more. Chronic spontaneous urticaria was previously referred to as chronic idiopathic urticaria. This term is no longer used as many cases have an autoimmune basis.
'Chronic Idiopathic Urticaria - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Idiopathic Urticaria pipeline landscape is provided which includes the disease overview and Chronic Idiopathic Urticaria treatment guidelines. The assessment part of the report embraces, in depth Chronic Idiopathic Urticaria commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Idiopathic Urticaria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Chronic Idiopathic Urticaria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Idiopathic Urticaria Emerging Drugs
Further product details are provided in the report……..
Chronic Idiopathic Urticaria: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Idiopathic Urticaria drugs segregated based on following parameters that define the scope of the report, such as:
Chronic Idiopathic Urticaria: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Idiopathic Urticaria therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Idiopathic Urticaria drugs.
Chronic Idiopathic Urticaria Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Chronic Idiopathic Urticaria - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Idiopathic Urticaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chronic Idiopathic Urticaria: Overview
Chronic Urticaria (CU) conventionally refers to recurrent wheals, on most days of the week, which occur for a period of ? six weeks. CU can be further divided into two different subtypes, namely, chronic idiopathic urticaria (also called chronic spontaneous urticaria) and chronic inducible urticaria (also called physical urticaria). In most patients, CU is a sporadic and self-limited disorder. Chronic spontaneous urticaria refers to chronic urticaria that has no specific cause or trigger. Weals are present on most days of the week for 6 weeks or more. Chronic spontaneous urticaria was previously referred to as chronic idiopathic urticaria. This term is no longer used as many cases have an autoimmune basis.
'Chronic Idiopathic Urticaria - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Idiopathic Urticaria pipeline landscape is provided which includes the disease overview and Chronic Idiopathic Urticaria treatment guidelines. The assessment part of the report embraces, in depth Chronic Idiopathic Urticaria commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Idiopathic Urticaria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Idiopathic Urticaria R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Idiopathic Urticaria.
This segment of the Chronic Idiopathic Urticaria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Idiopathic Urticaria Emerging Drugs
- Ligelizumab: Novartis
- Dupilumab: Regeneron
- Tezepelumab: Amgen
Further product details are provided in the report……..
Chronic Idiopathic Urticaria: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Idiopathic Urticaria drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chronic Idiopathic Urticaria
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Chronic Idiopathic Urticaria: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Idiopathic Urticaria therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Idiopathic Urticaria drugs.
Chronic Idiopathic Urticaria Report Insights
- Chronic Idiopathic Urticaria Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic Idiopathic Urticaria drugs?
- How many Chronic Idiopathic Urticaria drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Idiopathic Urticaria?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Idiopathic Urticaria therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic Idiopathic Urticaria and their status?
- What are the key designations that have been granted to the emerging drugs?
- Novartis
- Regeneron
- Amgen
- AstraZeneca
- United BioPharma
- Celltrion
- Celldex Therapeutics
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- Gilead Sciences
- Stero Biotechs Ltd.
- UCB Biopharma SRL
- GlaxoSmithKline
- UBP Greater China (Shanghai) Co., Ltd
- Genentech
- Kiniksa Pharmaceuticals, Ltd.
- Ligelizumab
- Dupilumab
- Tezepelumab
- Benralizumab
- UB-221
- CT-P39
- CDX-0159
- SYN008
- Tirabrutinib
- UCB8600
- Nucala
- UB-221
- GDC-0853
- KPL-716
Introduction
Executive Summary
Chronic Idiopathic Urticaria: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Ligelizumab: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tezepelumab: Amgen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
UCB8600: UCB Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chronic Idiopathic Urticaria Key Companies
Chronic Idiopathic Urticaria Key Products
Chronic Idiopathic Urticaria- Unmet Needs
Chronic Idiopathic Urticaria- Market Drivers and Barriers
Chronic Idiopathic Urticaria- Future Perspectives and Conclusion
Chronic Idiopathic Urticaria Analyst Views
Chronic Idiopathic Urticaria Key Companies
Appendix
Executive Summary
Chronic Idiopathic Urticaria: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Ligelizumab: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tezepelumab: Amgen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
UCB8600: UCB Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chronic Idiopathic Urticaria Key Companies
Chronic Idiopathic Urticaria Key Products
Chronic Idiopathic Urticaria- Unmet Needs
Chronic Idiopathic Urticaria- Market Drivers and Barriers
Chronic Idiopathic Urticaria- Future Perspectives and Conclusion
Chronic Idiopathic Urticaria Analyst Views
Chronic Idiopathic Urticaria Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Chronic Idiopathic Urticaria
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Chronic Idiopathic Urticaria
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Chronic Idiopathic Urticaria
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Chronic Idiopathic Urticaria
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
